Good MorningU.S. stock markets were relatively calm again on Tuesday as traders gear up for the Q1 earnings onslaught. The S&P 500 was able to edge higher but by less than half a percent to set a new all-time high. The market is being led higher by the analyst’s sentiment and a rising consensus for Q1 results. The risk for the market is that with the S&P 500 so highly valued there is a risk Q1 earnings could turn into a sell-the-news event.
Trading could take on a different tone after today. Between expected earnings reports from the big banks and economic data in the form of the Fed’s Beige Book, there is a lot of risk for the market. Among those reporting are J.P. Morgan, Goldman Sachs, and Wells Fargo. As for the Beige Book, the market will be watching it closely for any signs of rising inflation and there are sure to be some.
Featured: The government is eating your gains (Investpub (Wealthpress campaigns)) 
|
Markets | | | Back in March 2020, when lockdowns began and businesses were shut down, investors lost confidence in everything, even online payment systems such as PayPal (NASDAQ: PYPL), Square (NYSE: SQ) and Shift4 (NYSE: FOUR).
Read the Full Story |
|
From Our PartnersMillionaire Wall Street Legend Urges Americans To Get Out Of CASH before April 27th. | | Details here. |
|
Markets | | | Global stock markets and Wall Street futures rose Wednesday after traders shrugged off higher U.S. inflation and a decline in Japanese machinery orders.
London and Paris opened higher while Shanghai, Hong Kong and Seoul rose. Tokyo was off less than 0.5%.
On Tuesday, Wa... Read the Full Story |
|
Stocks | | | In the world of professional sports, defense often wins championships. In stock investing, defensive companies typically don't produce championship caliber returns.Here are three of those so-called defensive names that are up big this year—and may still be in the early innings of a bigger rally.
Read the Full Story |
|
|
Stocks | | | Dividend stocks can be a great way to hedge against inflation, especially if you choose companies that are known to increase their payouts over time. Let’s take a look at 3 dividend stocks to help you fight inflation below.
Read the Full Story |
|
Politics | | | WARSAW, Poland – Poland plans to go ahead with immunizations using the Johnson & Johnson vaccine after receiving its first batch of 120,000 doses on Wednesday.
Health Minister Adam Niedzielski said Poland is following the latest recommendations from the European Medicines Agency, ... Read the Full Story |
|
From Our PartnersIn this brand-new report, you’ll receive a deep-dive analysis on the fundamentals behind why the selected company may be a good fit for your portfolio over the next 12 months. Click Here To Get Immediate Access. You’ll also get a free subscription to Conservative Investor News’s Newsletter plus up to 2 additional free subscription! No CC Required, 100% free. Full Disclosures Found Here | | Click to get your free report |
|
Politics | | | Spain’s prime minister says that his government is maintaining its goal of immunizing 70% of the nation’s adult population by the end of the summer despite the delay in the European rollout of the Johnson & Johnson vaccine Read the Full Story |
|
Politics | | | German health authorities are recommending that people younger than 60 who have already received one shot of the AstraZeneca vaccine use a different vaccine for their second dose over concerns of blood clots Read the Full Story |
|
Tech | | | The president of Toshiba Corp. has stepped down, a week after the Japanese technology and manufacturing giant said it was studying an acquisition proposal from a global fund where he previously worked Read the Full Story |
|
Markets | | | The nation’s largest manufacturer of steel wire reinforcing products for concrete construction applications Insteel Industries (NYSE: IIIN) stock has been a pandemic benefactor thanks to the housing boom. Read the Full Story |
|
Markets | | | NXP Semiconductors (NASDAQ: NXPI) had a rough 2020. The company – which derives nearly half of its revenue from its automotive business – saw full-year revenue drop 3% yoy to $8.6 billion.
But that 3% dip doesn’t tell the whole story – it was an uneven year for NXP. In the s... Read the Full Story |
|
The Early Bird Stock Of The Day Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. | | View Today's Stock Pick |
|
